Company research
CervoMed Inc.
CIK 1053691Updated Sep 27, 2026
SecurityCRVO · NASDAQ · equity
Name history
Diffusion Pharmaceuticals Inc. · through Aug 14, 2023RestorGenex Corp · through Jan 14, 2016Stratus Media Group, Inc · through Mar 7, 2014FERIS INTERNATIONAL, INC. · through Jul 16, 2008TITAN MOTORCYCLE CO OF AMERICA INC · through Feb 22, 2008
CRVO price & chart
Loading TradingView…
NASDAQ:CRVO on TradingView ↗In the news
CervoMed to Participate in September Investor Conferences ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13G/A filing
SCHEDULE 13G/A filing
SCHEDULE 13G filing
SCHEDULE 13G filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
10-Q filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 22,879,018Source | 43,081,610Source | 9,972,521Source | 22,635,052Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 8,235,469Source | 8,999,496Source | 7,792,846Source | 10,113,706Source |
| Assets, CurrentUSD | 22,879,018Source | 43,081,610Source | 9,964,751Source | 22,635,052Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,267,005Source | 1,905,360Source | 1,256,501Source | — |
| Other Assets, NoncurrentUSD | — | 0Source | 7,770Source | 0Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,656,117Source | 3,879,282Source | 2,595,747Source | 2,417,336Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 9,252Source | 8,702Source | 5,674Source | 2,040Source |
| Additional Paid in CapitalUSD | 115,905,684Source | 109,868,913Source | 61,811,889Source | 165,847,590Source |
| Retained Earnings (Accumulated Deficit)USD | -97,697,851Source | -70,731,484Source | -54,440,789Source | -145,596,539Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,816Source | 56,197Source | — | -35,375Source |
| Stockholders' Equity Attributable to ParentUSD | 18,222,901Source | 39,202,328Source | 7,376,774Source | 20,217,716Source |
| Liabilities and EquityUSD | 22,879,018Source | 43,081,610Source | 9,972,521Source | 22,635,052Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,656,117Source | — | — | — |
| Accounts Payable, CurrentUSD | 1,454,118Source | 1,511,440Source | 662,471Source | 1,127,782Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 20,900,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 0Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,448,634Source | 1,405,722Source | 407,632Source | 928,052Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,827,238Source | 1,338,827Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | -67,322Source | 848,969Source | 565,169Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -23,449,963Source | -16,530,827Source | -7,449,847Source | -14,969,114Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 18,097,249Source | -28,661,129Source | — | -12,235,738Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,588,687Source | 46,398,606Source | 11,149,114Source | 5,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -764,027Source | 1,206,650Source | 3,699,267Source | -27,199,852Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 8,999,496Source | 7,792,846Source | 10,113,706Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,448,634Source | 1,405,722Source | 407,632Source | 928,052Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 20,900,000Source | — | — | — |
| Depreciation, NonproductionUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 10,484,315Source | 9,166,762Source | 6,519,268Source | 8,735,015Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | 0Source |
| Investment Income, InterestUSD | 1,336,837Source | 1,937,427Source | 219,430Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | 0Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | 56,197Source | — | -35,375Source |
| Net Income (Loss) Attributable to ParentUSD | -26,966,367Source | -16,290,695Source | -2,171,873Source | -15,591,428Source |
| Nonoperating Income (Expense)USD | 1,328,510Source | 1,936,436Source | 5,641,022Source | — |
| Operating ExpensesUSD | 32,301,387Source | 27,965,105Source | 14,957,767Source | — |
| Operating Lease, ExpenseUSD | 57,112Source | 34,692Source | 34,000Source | 18,000Source |
| Other Nonoperating Income (Expense)USD | -8,327Source | -991Source | 5,421,592Source | — |
| Proceeds from Issuance of Common StockUSD | — | 46,398,606Source | 810,000Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 4,006,510Source | 9,737,974Source | 7,144,872Source | — |
| Operating Income (Loss)USD | -28,294,877Source | -18,227,131Source | -7,812,895Source | -15,972,180Source |
| Other Nonoperating Income (Expense)USD | -8,327Source | -991Source | 5,421,592Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -15,591,428Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -26,966,367Source | -16,290,695Source | -2,171,873Source | -15,591,428Source |
| Earnings Per Share, BasicUSD per share | -2.98Source | -2.02Source | -0.82Source | -7.65Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | 2,038,891Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 9,041,760Source | 8,073,155Source | 2,661,416Source | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 10,484,315Source | 9,166,762Source | 6,519,268Source | 8,735,015Source |
| Interest ExpenseUSD | — | — | 0Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | 380,752Source |
| Investment Income, InterestUSD | 1,336,837Source | 1,937,427Source | 219,430Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | — | 0Source |
| Nonoperating Income (Expense)USD | 1,328,510Source | 1,936,436Source | 5,641,022Source | — |
| Operating ExpensesUSD | 32,301,387Source | 27,965,105Source | 14,957,767Source | — |
| Operating Lease, ExpenseUSD | 57,112Source | 34,692Source | 34,000Source | 18,000Source |
| Research and Development ExpenseUSD | 21,817,072Source | 18,798,343Source | 8,438,499Source | 7,237,165Source |